L-NAME (hydrochloride)

L-NAME (hydrochloride)

• CAS Number: 51298-62-5
• UNSPSC Description: L-NAME hydrochloride inhibits NOS with an IC50 of 70 μM. L-NAME is a precursor to NOS inhibitor L-NOARG which has an IC50 value of 1.4 μM.
• Target Antigen: NO Synthase
• Type: Reference compound
• Related Pathways: Immunology/Inflammation
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/L-NAME-hydrochloride.html
• Purity: 99.70
• Solubility: DMSO : 100 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)
• Smiles: N[C@@H](CCCNC(N[N+]([O-])=O)=N)C(OC)=O.[H]Cl
• Molecular Weight: 269.69
• References & Citations: [1]Pfeiffer S, et al. Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME): requirement forbioactivation to the free acid, NG-nitro-L-arginine. Br J Pharmacol. 1996 Jul;118(6):1433-40.|[2]Kopincová J, et al. L-NAME in the cardiovascular system - nitric oxide synthase activator? Pharmacol Rep. 2012;64(3):511-20.|[3]Lo HC, et al. The Nitric Oxide Synthase Inhibitor NG-Nitro-L-Arginine Methyl Ester Diminishes the Immunomodulatory Effects of Parental Arginine in Rats with Subacute Peritonitis. PLoSOne. 2016 Mar 23;11(3):e0151973.|[4]Luo H, et al. Effect of nitric oxide synthase inhibitor L-NAME on fear extinction in rats: a task-dependent effect. Neurosci Lett. 2014 Jun 20;572:13-8.|[5]Ocsan RJ, et al. Chronic NG-nitro-l-arginine methyl ester (L-NAME) administration in C57BL/6J mice induces a sustained decrease in c-kit positive cells during development of cardiac hypertrophy. J Physiol Pharmacol. 2013 Dec;64(6):727-36.|[6]V A Peotta, et al. Cardiovascular neural reflexes in L-NAME-induced hypertension in mice. Hypertension. 2001, 38, 3.|[7]Xiaofei Li, et al. Fucoidan from Undaria pinnatifida prevents vascular dysfunction through PI3K/Akt/eNOS-dependent mechanisms in the l-NAME-induced hypertensive rat model. Food Funct. 2016, 7, 5.Adv Sci (Weinh). 2024 Apr 3:e2309002.|Arterioscler Thromb Vasc Biol. 2020 Jul;40(7):1705-1721.|Bioengineered. 2022 Jan;13(1):1320-1334.|Biomed Pharmacother. 2019 Jul;115:108934. |Biomed Pharmacother. 2023 Mar 13;161:114484.|Biomed Res Int. 2021 May 15.|bioRxiv. 2023 Dec 4.|bioRxiv. 2023 Nov 1.|BMC Nephrol. 2024 Jul 15;25(1):226.|Bosn J Basic Med Sci. 2017 May 20;17(2):132-137.|Cancer Metab. 2024 May 17;12(1):14.|Cancer Res. 2024 Mar 19.|Cardiovasc Diabetol. 2024 May 9;23(1):164.|Cell Commun Signal. 2021 Mar 18;19(1):35.|Evid Based Complement Alternat Med. 2020 Mar 10;2020:3524641.|Exp Ther Med. 2018 Aug;16(2):1079-1086.|FASEB J. 2024 Jul 31;38(14):e23844.|Free Radic Biol Med. 2024 Sep 13:S0891-5849(24)00659-2.|Front Cardiovasc Med. 2021 Apr 13;8:654254.|Front Med. 2021 Apr 13;8:634882.|Hum Gene Ther. 2022 Nov 14.|Insect Mol Biol. 2024 Jan 5.|Int Immunopharmacol. 2023 Dec 21:127:111313.|Int J Immunopathol Pharmacol. Jan-Dec 2022;36:3946320221111117.|Int J Mol Med. 2024 Aug;54(2):67.|Int J Mol Sci. 2023 Mar 7.|J Cardiovasc Transl Res. 2024 Jul 9.|J Cell Mol Med. 2024 Apr;28(8):1-11.|J Ethnopharmacol. 2022 Jun 17;115476.|J Extracell Vesicles. 2023 May;12(5):e12328.|JCI Insight. 2021 Sep 22;6(18):e133690.|Mediat Inflamm. 2019 Oct 7;2019:6168340.|Mediat Inflamm. 2020 Oct 24;2020:1649453.|Microvasc Res. 2023 Mar 22;148:104531.|Mol Cell Probes. 2023 Feb 2;67:101896.|Nutrients. 2022, 14(23), 5025|PeerJ. 2023 May 25.|Phytomedicine. 6 June 2022, 154242.|Placenta. 12 November 2021.|Placenta. 2021 Feb 11.|Research Square Preprint. 2021 Feb.|Research Square Preprint. 2022 May.|Research Square Preprint. 2023 May 30.|Toxicol Appl Pharmacol. 2019 Mar 1;366:83-95. |Vet Microbiol. 19 July 2022, 109514.|Biomed Pharmacother. 2020 Aug;128:110240.|Cell Tissue Res. 2022 Jan 29.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C (Powder, sealed storage, away from moisture)
• Clinical Information: Phase 3